IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.

$12.900.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume0
Today's Open$0.00
Previous Close$12.90
Data as of 06/20/18 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
06/11/18Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
Data indicate that self-renewing pools of SPEAR T-cells can produce a continuous supply of effector cells capable of mediating sustained antitumor effects PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑cells in synovial sarcoma will be published in Cancer Discovery (an American Association of Cancer Research [AACR]... 
Printer Friendly Version
06/04/18Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD, U.K., June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and the triple tumor study in bl... 
Printer Friendly Version
06/04/18Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -              - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study - PHILADELPHIA, Pa. and OXFORD, U.K., June 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the independent safety review committee has recommended dose escalation in the MAGE-A4 basket study, based on an ac... 
Printer Friendly Version
06/02/18Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). With eight patients treated, the best overall responses include three confirmed partial responses, one unconfirmed partial response, three stable disease, and one recently treated patient awaiting assessment. These da... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.